Physician profile
George Heading
NPI 1548364532
$7,655.11
in general payments reported to CMS, 2019-2025
37 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,133 · 2020: $498 · 2021: $1,402 · 2022: $1,413 · 2023: $1,126 · 2024: $778 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,219.82 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $1,072.82 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $814.67 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $422.07 | 2023-2025 | Gemtesa, Myfembree |
| Pfizer INC. | $417.79 | 2019-2025 | |
| Therapeuticsmd, INC. | $402.13 | 2019-2022 | |
| Avion Pharmaceuticals | $353.67 | 2019-2022 | |
| Exeltis, USA INC. | $289.30 | 2019-2025 | Slynd |
| Aspira Women'S Health INC | $280.96 | 2021-2025 | Ova1 |
| Exact Sciences Corporation | $267.05 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $257.70 | 2021-2022 | |
| Biogen, INC. | $236.20 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $223.53 | 2019-2025 | |
| Urovant Sciences INC | $223.17 | 2021-2022 | |
| Coopersurgical, INC. | $161.52 | 2019-2025 | Paragard T 380a, Paragard T 380a |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $131.57 | 2019-2025 | Intrarosa, Femlyv |
| Scynexis, INC. | $95.46 | 2022 | |
| Evofem Biosciences, INC. | $90.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $84.00 | 2019-2023 | Gardasil 9 |
| Caldera Medical, INC | $83.47 | 2021 | |
| Vertical Pharmaceuticals, LLC | $65.66 | 2019 | |
| Amag Pharmaceuticals, INC. | $56.66 | 2019 | |
| Duchesnay USA Incorporated | $49.66 | 2019 | |
| Agile Therapeutics, INC. | $43.21 | 2021-2022 | |
| Allergan, INC. | $43.10 | 2019-2020 | |
| Mission Pharmacal Company | $38.58 | 2019-2020 | |
| Lupin INC. | $32.40 | 2020-2021 | |
| Coloplast Corp | $31.57 | 2019-2020 | |
| Daiichi Sankyo INC. | $29.96 | 2019 | |
| Baxter Healthcare | $25.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.80 | 2019 | |
| Ascend Therapeutics US, LLC | $22.01 | 2021 | |
| Sanara Medtech INC. | $21.27 | 2021 | |
| Organon LLC | $16.68 | 2025 | Nexplanon |
| Olympus America INC. | $12.99 | 2019 | |
| Medicem INC. | $11.48 | 2020 | |
| Meditrina | $4.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Heading listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.